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Drug-loaded chitosan ﬁlm prepared via facile solution casting and air-drying
of plain water-based chitosan solution for ocular drug delivery
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Chitosan is a nature-based polymer with low toxicity, excellent biocompatibility and biodegradability. However,
the intractable solubility of chitosan in water and most conventional solvents hampers its biomedical applications. Following the dissolution method for dissolving chitosan in plain water developed by us, chitosan was
dissolved in ionic liquid followed by overnight freezing at −20 °C and subsequent solvent exchange with plain
water at room temperature. In this study, we fabricated a drug-carrying chitosan ﬁlm via solution casting and
air-drying by using the plain water-based chitosan solution. Speciﬁcally, brimonidine tartrate (BT), an antiglaucoma drug, was dissolved in the plain-water based solution and used to prepare BT-loaded chitosan ﬁlm, i.e.,
chitosan-BT ﬁlm. The resulting ﬁlm is transparent, structurally stable, and mucoadhesive. Micro-sized antiglaucoma BT drug crystals form and are well dispersed in the chitosan ﬁlm. The chitosan-BT ﬁlm enables BT to
have a high corneal permeability with fast drug release kinetics for potential ocular drug delivery.

1. Introduction
Chitosan is a nature-based polymer commonly obtained from the
deacetylation of chitin, one of the most abundant and renewable biopolymers on the earth after cellulose. Due to good biocompatibility and
biodegradability, chitosan has broad applications in the ﬁelds of cosmetic, food, pharmaceutical and biomedicine [1–10]. Food and Drug
Administration (FDA) has approved chitosan-based wound dressings
[11]. Inheriting biologically desired characteristics such as anti-bacteria and bioadhesion, chitosan ﬁlms have been used as food wraps,
artiﬁcial skins, contact lenses and so on [12–15]. However, the poor
solubility of chitosan is still an issue for fabrication. It is diﬃcult to
dissolve chitosan into water and most solvents because of the intermolecular and intramolecular hydrogen-bonded network [16].
Acids like acetic acid are commonly used to dissolve chitosan [17].
However, the use of acids may involve many corrosive processes and
the acid residues may aﬀect the skin, mucosa, tissue and so on. Alkali
neutralization and water washing usually follow the acid treatment to

remove acids from chitosan. Nevertheless, the residues of acids and
alkalis may remain in products and have adverse biological eﬀects. In
addition, it remains a challenge to incorporate water-soluble compounds into chitosan during the solubilization process. Recently, ionic
liquids (ILs) have received much attention as solvents for chitosan solubilization because of their compelling features, such as non-volatile,
high thermal and chemical stability, and easy to recycle [18]. ILs are
more environmentally friendly and the chitosan/ILs systems have better
processability to develop chitosan materials [18]. Although previous
studies showed that some ionic liquids are relatively safe for industrial
applications, the toxicity of ionic liquids still needs to be further elucidated to support the biological use of chitosan/ILs systems [19,20].
Plain water can be the safest and the most applicable solvent to develop
chitosan-based biomedical materials. In our previous study, we developed an ecofriendly method for dissolving chitosan in plain water [21].
In the method, chitosan was ﬁrst dissolved in the ionic liquid EMIM Ac
and then the chitosan/ionic liquid mixture was kept at −20 °C overnight. Then, the extensive solvent exchange with plain water at room
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determined by immersing chitosan ﬁlm in PBS (pH 7.4, 1 × ) at 37 °C.
The swollen chitosan ﬁlm was gently taken out and weighted at different time intervals. The measurement duration was up to 24 h in
order to reach the maximum absorption. The swelling ratio was calculated by: Swelling ratio (%) = (Wt - W0)/W0 × 100, where Wt represents the mass of the swollen sample at time point t and W0 represents the initial mass of the sample.
Stability Studies. The stability of chitosan ﬁlm was investigated by
monitoring the mass of the chitosan ﬁlm after swelling equilibrium in
PBS (pH 7.4, 1 × ) at 37 °C. The chitosan ﬁlm was immersed in PBS (pH
7.4, 1 × ) at 37 °C and the mass of the swollen chitosan ﬁlm at 24 h was
taken as the initial mass (ms). The mass of the swollen sample at time
point t is deﬁned as mt. The ratio of mt/ms represents the weight change
and the stability of the chitosan ﬁlm.
Light Transmittance. The visible light transmittance of the chitosan
ﬁlm was measured with a UV–Vis spectrophotometer (Evolution 201) in
the wavelength range from 400 to 800 nm.
Cytotoxicity Assessment. Cytotoxicity of the chitosan ﬁlm was evaluated on both NIH3T3 mouse embryo ﬁbroblasts cells and primary
human corneal epithelial (HCE) cells. HCE cells, derived from normal
human corneal tissue, were cultured following the manufacturer's instructions in complete corneal epithelial cell growth medium. HCE cells
within third passages were used. Chitosan ﬁlm was sterilized by UV
irradiation before use. NIHT3T3 cells were seeded in a 6-well plate at a
density of 5 × 105 cells/well. HCE cells were seeded in a 12-well plate
at a density of 5 × 104 cells/well. The cells were cultured for 24 h to
allow attachment. Sterilized chitosan ﬁlm was put in an insert with
diﬀerent doses. The inserts loaded with chitosan ﬁlms were placed in
the wells, immersed by cell culture medium without contacting with the
cells. After 24-h culture, the cytotoxicity was analyzed by WST-1 assay.
For quantiﬁcation of cytokines, 600 μL of the culture media of HCE cells
was collected and centrifuged after 6-h culturing. The supernatants
were subjected to ELISA analysis following the manufacturer's instructions.
Mucoadhesion Tests. To assess mucoadhesive properties of the chitosan ﬁlm, a series of mucin aqueous solutions were prepared for
quantitative analysis of the interaction between mucin particles and the
chitosan ﬁlm [32]. A standard curve was created by using Pierce™ BCA
protein assay kit following the manufacture's procedure with diﬀerent
mucin concentrations (2000, 1500, 1000, 500, 200, 100, and 20 μg/
mL). Chitosan ﬁlm (~1.43 mg, ~2.30 cm2) was added to 1 mL of as
prepared mucin solution (2 mg/mL). After determined time points (1 h,
2 h, and 24 h), the concentration of the mucin solution was analyzed
using the same assay kit as the standard curve. The mucoadhesive
property of the chitosan ﬁlm was calculated by (m0-mt)/s, where m0 is
the mass of mucin in the solution before chitosan ﬁlm adsorption, mt is
the mass of mucin in the solution after chitosan ﬁlm adsorption, s is the
adsorption area of the chitosan ﬁlm. The adsorption area of 1.43 mg
chitosan ﬁlm is about 4.60 cm2.
In Vitro Drug Release Kinetics. Drug release from chitosan-BT ﬁlm
was performed. Brieﬂy, 0.8 mg of chitosan-BT ﬁlm containing about
222 μg of BT was immersed in 1 mL of PBS in a centrifuge tube. The
tube was maintained at 37 °C. At predetermined time intervals, 1 mL of
PBS medium was withdrawn, and 1 mL of fresh PBS was added to
maintain a constant volume. The BT concentration in the withdrawn
PBS medium was analyzed on HPLC based on a standard curve of BT.
All experiments were performed in triplicate.
Ex Vivo Permeation Studies. The corneal permeability of BT in the
chitosan-BT ﬁlm was evaluated in a Franz diﬀusion cell system
(PermeGear, Hellertown, PA) [33]. The Franz diﬀusion cell had a diffusion area of 0.785 cm2 with a donor chamber and a receiver chamber.
Cornea wasextracted from fresh rabbit eye and immediately mounted in
the diﬀusion cell with the epithelial surface facing the donor chamber
and the endothelial surface facing the acceptor chamber. A rounded
chitosan-BT ﬁlm with a 6 mm diameter attached to the cornea epithelial
surface and loaded in the donor chamber with 200 μL of PBS. The

temperature was conducted to obtain a stable dispersion of nanosized
chitosan in plain water. In the process, the hydrogen-bonded network of
chitosan is disrupted by the ionic liquid to free the amines that participate in hydrogen bonding. The intermediate freezing step prevents
the dissolved chitosan from reconnecting with hydrogen-bonding interactions. The solvent-exchange step leads to the protonation of chitosan's amine groups, which in turn promotes chitosan solvation in plain
water. This method eliminates solvent eﬀects and skips tedious postsolubilization processes. Furthermore, it opens up opportunities to develop and apply chitosan-based products for those biomedical applications that depend critically on safer formulations such as ocular drug
delivery.
In this work, we developed an ocular drug-loaded chitosan ﬁlm by
using the plain water-based chitosan solution. Drug-carrying ﬁlm materials such as therapeutic contact lenses have been applied to treat eye
diseases recently [22–26]. Brimonidine tartrate (BT) is an antiglaucoma
drug commonly taken in the form of eye drops. The eﬃcacy of BT can
be improved in many aspects through the use of polymer carriers
[27–31]. In our new formulation, micro-sized brimonidine tartrate
crystals formed within the chitosan ﬁlm through the solution casting
and air-drying process. The SEM, swelling, stability and light transmittance experiments were conducted to characterize the chitosan ﬁlm.
The cytotoxicity and mucoadhesion for the obtained ﬁlm were also
investigated. The drug release kinetics and permeability of BT in the
form of the chitosan-BT ﬁlm were studied. With excellent biocompatibility and high corneal permeability of the drug, this drug-carried
chitosan ﬁlm can be potentially used for ocular drug delivery.
2. Materials and methods
2.1. Materials
Chitosan
with
high
molecular
weight
(HMW)
(310,000–375,000 Da), ionic liquid 1-ethyl-3-methylimidazolium
acetate (EMIM Ac, ≥95.0%) and cell proliferation reagent WST-1 were
purchased from Sigma-Aldrich (St. Louis, MO). Brimonidine tartrate
(BT) (salt form) was purchased from AvaChem Scientiﬁc (San Antonio,
TX). Water (HPLC grade), acetonitrile (ACN, HPLC grade), triﬂuoroacetic acid (TFA), phosphate-buﬀered saline (PBS, 10 × ), ELISA
kits of human IL-6, IL-β and TNF-α were purchased from Thermo Fisher
Scientiﬁc (Logan, UT). Gastric porcine mucin was purchased from
PFALTZ&BAUER, Inc. (CT, USA). The concentration of mucin was
measure by Pierce™ BCA protein assay kit purchased from Thermo
Fisher. Fresh rabbit whole eyes were purchased from Pel-Freeze
Biologicals (Rogers, AR). Rhodamine B (RB) was purchased from Fluka.
2.2. Methods
Preparation of Chitosan Films. The plain water-based chitosan solution was prepared following our previous method [21]. Brieﬂy, the
HMW chitosan was dissolved in ionic liquid EMIM Ac and frozen
overnight, then solvent exchanged with plain water to form the plain
water-based chitosan solution with a concentration of about 2.4 mg/mL
[21]. Chitosan ﬁlm was prepared by casting 2 mL of the plain waterbased chitosan solution into a rounded polytetraﬂuoroethylene (PTFE)
mold with a diameter of 32 mm followed by air-drying overnight.
Brimonidine tartrate (BT) was dissolved in the plain water-based chitosan solution with a concentration of 1 mg/mL. Following the same
casting-drying method, chitosan-BT ﬁlm was prepared. Rose-colored
chitosan-RB ﬁlm was also prepared. The obtained ﬁlms were punched
by a 6 mm-diameter puncher for further use (Fig. 1).
Scanning Electron Microscopy (SEM). Chitosan ﬁlm and chitosan-BT
ﬁlms (before and after drug release) were sputter-coated with platinum
for 90 s. Then, SEM images were taken on a scanning electron microscope (Hitachi FE-SEM Su-70, Japan).
Swelling Studies. The swelling behavior of the chitosan ﬁlm was
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Fig. 1. Preparation of chitosan ﬁlm and chitosan-BT ﬁlm.

BT ﬁlm before and after drug release. As shown in Fig. 2a and b, a
smooth chitosan ﬁlm was obtained after evaporating the solvent of
plain water at room temperature. The thickness of the chitosan ﬁlm is
about 3.5 μm. After dissolving of brimonidine tartrate (BT) in the plain
water-based chitosan solution, a chitosan-BT ﬁlm was prepared. BT
crystals are uniformly formed and well dispersed in the chitosan ﬁlm, as
shown in Fig. 2c. Submicron/micro-sized BT particles (Fig. 2c inset) are
loaded on the surface and inserted into the inside of the chitosan ﬁlm
(Fig. 2d). After drug release from the chitosan-BT ﬁlm, micro-sized BT
crystals disappear from the smooth chitosan ﬁlm (Fig. 2e and f).
As shown in Fig. 3, the swelling ratio of the chitosan ﬁlm reaches to
1987% at 6 min and exceeds 2000% within 15 min. Then, the swelling
ratio ﬂuctuates around 2300% for a swelling equilibrium. The high
swelling capacity of the chitosan ﬁlm in PBS is attributed to the extremely hydrophilic nature and the high aﬃnity to the salt solutions of
chitosan due to the hydroxy and amino groups [34,35]. In this study, a
chitosan ﬁlm formed following solution casting and air-drying of the
plain water-based chitosan solution. During the chitosan solution preparation, the hydrogen-bonded network of chitosan was disrupted, and

receiver chamber of the diﬀusion cell was ﬁlled with 5 mL of PBS. At
predetermined time points up to 1 h, an aliquot of 500 μL PBS was
withdrawn from the receiver chamber and analyzed by HPLC, and fresh
PBS (500 μL) was added to the receiver chamber after each sampling.
All the experiments were conducted in triplicate. The permeability
coeﬃcient, P, was calculated as follows: P = (dQ/dt)/AC, where dQ/dt
is the steady-state slope of a cumulative ﬂux curve, C is the loading
concentration of BT in the donor chamber, and A is the eﬀective crosssectional area (0.785 cm2) for diﬀusion. Flux (μg/cm2/h) is determined
by (dQ/dt)/A [33].
Statistical Analysis. The data were reported as means ± standard
deviation (SD). Student's t-test was conducted for statistical analysis. P
values less than 0.05 were considered statistically signiﬁcant.

3. Results and discussion
The chitosan ﬁlm and chitosan-BT ﬁlm were prepared through a
solution casting and air-drying process with plain water as the solvent
(Fig. 1). Fig. 2 shows the SEM images of the chitosan ﬁlm and chitosan-

Fig. 2. SEM images of chitosan ﬁlm (a, b), chitosan-BT ﬁlm (c, d), and chitosan-BT ﬁlm after drug release (e, f).
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Fig. 3. Swelling behavior of chitosan ﬁlm in PBS at 37 °C.

Fig. 5. Transmittance spectrum of the chitosan ﬁlm. Inset: chitosan ﬁlm shows
excellent optical transparency.

the chitosan system experienced a signiﬁcant volume expansion during
solvation [21]. Upon drying, the hydrogen-bonded network restores
and the chitosan ﬁlm forms, in which chitosan molecules are connected
via a relatively extended chain conformation, leading to increased exposure of hydrophilic functional groups (hydroxy and amino groups).
This is presumably attributed to the unusually high swelling ratio for
the ﬁlm prepared using our method compared with chitosan ﬁlm prepared using the traditional method [36]. The chitosan ﬁlm has a high
swelling ratio in PBS, an attribute enabling drug carrier to eﬃciently
release drug to the aqueous environment via swelling-controlled diffusion.
The stability of the chitosan ﬁlm is shown in Fig. 4. Good stability
has been found for the chitosan ﬁlm with no obvious change of the
weight ratio over 35 days. By using an ecofriendly method in our previous study, a plain water-based chitosan solution was prepared
through breaking the hydrogen-bonded network of chitosan and the
chitosan amino groups are protonated by water molecules [21]. As the
removal of plain water by air-dying, the hydrogen-bonded interactions
among chitosan macromolecules restore, and a stable chitosan ﬁlm
forms with the recovered hydrogen-bonded network. The obtained
chitosan ﬁlm is stable and insoluble in PBS. It is possible to develop this
chitosan ﬁlm as a stable drug-carrier such as ocular insert.
Fig. 5 shows the transmittance spectrum and photograph of the
chitosan ﬁlm. The chitosan ﬁlm is ﬂexible and transparent (Fig. 5,

inset). Good light transmittance was exhibited by the chitosan ﬁlm with
a light transmittance value of over 70% from 400 nm to 800 nm. Many
transparent ﬁlm materials as functional contact lenses showed improved eﬀects for eye treatment [15,22–26]. As a transparent ﬁlm, this
chitosan material can be potentially composed of a contact lens for
ocular drug release.
The compatibility of the chitosan ﬁlm was studied by cytotoxicity
assessments on both NIH3T3 cells and HCE cells, as shown in Fig. 6. The
cytotoxicity was not observed on NIH3T3 cells when the concentration
of chitosan ﬁlm is up to 1050 μg/mL (Fig. 6a). When the concentration
of chitosan ﬁlm is lower than 808 μg/mL, the chitosan ﬁlm is also cytocompatible on HCE cells, as shown in Fig. 6b. IL-6, IL-β, and TNF-α
cytokines on the HCE cells were analyzed following treatment with
chitosan ﬁlm at 269, 403, and 808 μg/mL. The chitosan ﬁlm does not
accelerate the secretion of IL-β and TNF-α. No IL-β and TNF-α signals
were detected in the experiments. Chitosan ﬁlm at concentrations of
403 and 808 μg/mL partly decreases the IL-6 levels on HCE cells
(Fig. 6c). Generally, the cytotoxicity of the chitosan ﬁlm was not observed according to the viability assessments of NIH3T3 cells and HCE
cells. Chitosan is considered to be a biomaterial with very low toxicity
[37]. Avoiding the solvent eﬀects, chitosan products can practically
meet the need of bioapplication. The chitosan ﬁlm prepared from the
solvent of plain water shows excellent compatibility for biomedical
uses.
The mucoadhesive properties of the chitosan ﬁlm were tested by its
interactions with mucin [32]. When adding a polymer ﬁlm into a mucin
solution, the concentration of the mucin would decrease if the polymer
ﬁlm has the aﬃnity to the mucin. As shown in Fig. 7, the concentration
of the mucin solution drops from 2000 μg/mL to ~1500 μg/mL at 1 h,
and to ~1400 μg/mL over 2 h. The absorption of mucin particles on
chitosan ﬁlm (~1.43 mg) accounts for the decrease of the mucin concentration, which indicates the mucoadhesive properties of the chitosan
ﬁlm. The mucoadhesive property of the chitosan ﬁlm to mucin is about
128 μg/cm2. The mucoadhesive property of the chitosan to mucin is
attributed to their many interactions, such as hydrogen bonding, electrostatic interactions, hydrophobic eﬀects and so on [38]. The mucoadhesive chitosan ﬁlm has a great potential for transmucosal administration.
In vitro drug release kinetics of BT for the chitosan-BT ﬁlm in PBS at
37 °C are shown in Fig. 8. BT is released quickly from the chitosan-BT
ﬁlm. More than 75% of the drug is released within 6 min, and about
90% of drug is released less than half an hour. The remaining BT drug
shows a relatively slow release. The chitosan ﬁlm is extremely hydrophilic, and water solution can be easily absorbed by the chitosan ﬁlm as

Fig. 4. Stability of chitosan ﬁlm in PBS at 37 °C.
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Fig. 6. Cytotoxicity on (a) NIH3T3 cells, (b) HCE cells, and (c) cytokine IL-6 expression on HCE cells (n = 4). N.S. indicates not signiﬁcant, ** indicates p < 0.01 and
*** indicates p < 0.001.

As a model to show the practical release to the eye globe, a rhodamine B (RB)-loaded chitosan ﬁlm (chitosan-RB ﬁlm) has been prepared using the same method as the chitosan-BT ﬁlm. The chitosan-RB
ﬁlm and the rabbit eye globe are chosen to demonstrate the release
behavior as shown in Fig. 9. A rose-colored chitosan ﬁlm was obtained
(Fig. 9a). As shown in Fig. 9b, the chitosan-RB ﬁlm on the rabbit eye
globe shows good mucoadhesion. The mucoadhesive property of the
chitosan ﬁlm is further supported by the mucin experiments (Fig. 7).
The chitosan-RB ﬁlm almost turns transparent after release, and RB is
well released onto the rabbit globe as shown in Fig. 9c. The light
transmission of the chitosan ﬁlm (Fig. 5) would maintain after the release of RB. It is consistent with the fast release behavior of chitosan-BT
ﬁlm with about 75% BT drug having been released in 6 min as shown in
Fig. 8.
The transport of BT across the rabbit cornea was further studied
with the chitosan-BT ﬁlm. As shown in Fig. 10, the cumulative ﬂux
curve of BT displays a linear increase within the ﬁrst 30 min and
reaches a plateau afterward. The permeability is then calculated according to the linear range (Fig. 10 inset) of the cumulative ﬂux curves.
The cornea permeability of BT in the chitosan-BT ﬁlm is determined to
be 1.62 × 10−5 cm/s, which is much higher than the permeation
coeﬃcient from many previous systems [28,30]. Typical permeability
coeﬃcient for brimonidine range is between 2.1 × 10−7 and
3.6 × 10−7 cm/s [28,39]. Nano/micro-sized drug preparations can
improve drug solubility and bioavailability due to the large surface area
[40,41]. The micro-sized BT preparation through the chitosan ﬁlm
(Fig. 2) can signiﬁcantly improve the BT transport across the cornea for
ocular release. Although the release of BT is fast, this chitosan-BT ﬁlm
could possibly be an alternative of eye drops since the released BT can
eﬃciently cross the cornea.

Fig. 7. Concentration of mucin in the aqueous solutions with chitosan ﬁlm.

4. Conclusion
In this work, a chitosan ﬁlm loaded with micro-sized drug was
prepared using a simple and ecofriendly method based on solution
casting and air-drying of plain water-based chitosan solution.
Brimonidine tartrate (BT) as a model drug was incorporated to form a
chitosan-BT ﬁlm. Micro-sized BT crystals uniformly form and are dispersed in the chitosan ﬁlm. The chitosan ﬁlm is transparent and stable
with good properties of mucoadhesion and biocompatibility. BT is released fast from the chitosan-BT ﬁlm but has a high cornea permeability. This chitosan-BT ﬁlm has a great potential to be used for ocular
drug delivery.

Fig. 8. In vitro release kinetics of brimonidine tartrate from chitosan-BT ﬁlm in
PBS at 37 °C.

shown from the results of the swelling behavior (Fig. 3). With a large
surface area, micro-sized BT drug would fast dissolve in the aqueous
environment. According to the results of drug release (Fig. 8) and SEM
(Fig. 2), the fast release is from the fast-dissolved BT particles loaded on
the surface of the chitosan-BT ﬁlm, and the relatively slow release is
attributed to the remaining drug inserted into the inside of the chitosanBT ﬁlm.
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Fig. 9. Chitosan-RB ﬁlm releases RB to the rabbit eye. (a) Before the application, (b) attachment of the chitosan-RB ﬁlm onto the rabbit eye for 6 min, and (c) removal
of the ﬁlm.
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